A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine

Journal of Crohn's and Colitis

Volumn 4, Issue 5, 2010, Pages 546-552

  Gerich, Mark E ^a   Quiros, J Antonio ^a,b   Marcin, James P ^a   Tennyson, Linda ^a   Henthorn, Maria ^a   Prindiville, Thomas P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

6 MMP; 6 MP; 6 TG; Allopurinol; IBD; Thiopurine; TPMT

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; ALLOPURINOL; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CROHN DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; MIDDLE AGED; PHENOTYPE; PREVALENCE; PROSPECTIVE STUDIES; THIONUCLEOTIDES; YOUNG ADULT;

EID: 77958152828     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.03.004     Document Type: Article

References (39)

1. Sandborn W., Sutherland L., Pearson D., et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000, CD000545.
2. Pearson D.C., May G.R., Fick G., et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000, CD000067.
3. Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, CD000478.
4. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
5. Markowitz J., Grancher K., Kohn N., et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
6. Pearson D.C., May G.R., Fick G.H., et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 123:132-142.
7. Vermeire S., Noman M., van Assche G., et al. The effectiveness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in Crohn's disease. Gut 2007.
8. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
9. Present D.H., Korelitz B.I., Wisch N., et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980, 302:981-987.
10. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000545.
11. Gisbert J.P., Linares P.M., McNicholl A.G., et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009, 30:126-137.
12. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43:329-339.
13. Tiede I., Fritz G., Strand S., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003, 111:1133-1145.
14. Poppe D., Tiede I., Fritz G., et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006, 176:640-651.
15. Cuffari C., Theoret Y., Latour S., et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401-406.
16. Cuffari C., Hunt S., Bayless T.M. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000, 14:1009-1014.
17. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
18. Cuffari C., Hunt S., Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001, 48:642-646.
19. Hindorf U., Lindqvist M., Hildebrand H., et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006, 24:331-342.
20. Roblin X., Serre-Debeauvais F., Phelip J.M., et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005, 21:829-839.
21. Osterman, Kundu, Lichtenstein, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047-1053.
22. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651-662.
23. Dubinsky M.C., Yang H., Hassard P.V., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
24. Sparrow M.P., Hande S.A., Friedman S., et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5:209-214.
25. Sparrow M.P., Hande S.A., Friedman S., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22:441-446.
26. Ansari A., Hassan C., Duley J., et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1743-1750.
27. Oldenburg B., Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up?. Curr Opin Gastroenterology 2007, 23:395-399.
28. Bloomfeld R.S., Onken J.E. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003, 17:69-73.
29. Gearry R.B., Roberts R.L., Barclay M.L., et al. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004, 14:779-781.
30. Goldenberg B.A., Rawsthorne P., Bernstein C.N. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004, 99:1744-1748.
31. Gearry R.B., Barclay M.L., Roberts R.L., et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005, 35:580-585.
32. Corominas H., Domenech M., Gonzalez D., et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000, 95:2313-2317.
33. Reuther L.O., Sonne J., Larsen N., et al. Thiopurine methyltransferase genotype distribution in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 17:65-68.
34. Lennard L., Lilleyman J.S., Van Loon J., et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990, 336:225-229.
35. Snow J.L., Gibson L.E. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995, 131:193-197.
36. Chocair P.R., Duley J.A., Simmonds H.A., et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992, 53:1051-1056.
37. Chocair P.R., Duley J.A., Sabbaga E., et al. Fast and slow methylators: do racial differences influence risk of allograft rejection?. Q J Med 1993, 86:359-363.
38. Holme S.A., Duley J.A., Sanderson J., et al. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. Q J Med 2002, 95:439-444.
39. Seidman E.G. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003, 3(Suppl 1):S30-S38.